False positive galactomannan results in adult hematological patients treated with piperacillin-tazobactam

Revista Iberoamericana de Micologia

Volumn 24, Issue 2, 2007, Pages 106-112

  Alhambra, Almudena ^a   Cuétara, Ma Soledad ^b   Ortiz, Ma Cruz ^a   Moreno, Juan Marcos ^a   Del Palacio, Angel ^a   Pontón, José ^c   Del Palacio, Amalia ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL SEVERO OCHOA   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Aspergillosis; Diagnosis; False positives; Galactomannan; Piperacillin tazobactam

Indexed keywords

GALACTOMANNAN; PIPERACILLIN PLUS TAZOBACTAM;

ARTICLE; ASPERGILLUS; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; MUCOSA INFLAMMATION; SENSITIVITY AND SPECIFICITY;

ASPERGILLUS;

EID: 34347379063     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(07)70023-2     Document Type: Article

References (48)

1. Adam O, Aupérin A, Wilquin F, Bourhis JH, Gachot B, Gachaty E. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38: 917-920.
2. Allan EK, Jordanides NE, McLintock LA, Copland M, Devaney M, Stewart K. Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. Br J Haematol 2005; 128: 578-579.
3. Ansorg R, van del Boom R, Rath PM. Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses 1997; 40: 353-357.
4. Ascioglu SJ, Rex JH, de Pauw B, Bennet JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and haematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
5. Aubry A, Porcher R, Bottero J, Touratier S, Leblanc T, Brethon B, Rousselot P, Raffoux E, Menotti J, Derouin F, Ribaud P, Sulahian A. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with β-Lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006; 44: 389-394.
6. Bart-Delabesse E, Basile M, Al Jijakli A, Souville D, Gay F, Philippe B, Bossi R Danis M, Vernant JP, Datry A. Detection of Aspergillus galactomannan antigenemia to determine biological and clinical implications of beta-lactam treatments. J Clin Microbiol 2005; 43: 5214-5220.
7. Chamilos G, Luna M, Lewis RE, Safdar A, Bodey GP, Raad II, Kontoyiannis DP. Invasive fungal infections in patients with haematologic malignancies in a tertiary care cancer center: an autopsy over a 15 year period (1989-2003). Haematologica 2006; 91: 986-989.
8. Dalle F, Charles PE, Blanc K, Caillot D, Chavanet P, Dromer F, Bonnin A. Cryptococcus neoformans galactotoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus galactomannan. J Clin Microbiol 2005; 43: 2929-2931.
9. Denning DW. Early diagnosis of invasive aspergillosis. Lancet 2000; 355: 423-424.
10. Denning DW, Evans EG, Kibbler CC, Richardson MD, Roberts MM, Rogers TR, Warnock DW, Warren RE. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. Eur J Clin Microbiol Infect Dis 1997; 16: 424-436.
11. El Saleeby CM, Allison KJ, Knapp KM, Walsh TJ, Hayden RT. Discordant rise in galactomannan antigenemia in a patient with resolving aspergillosis, renal failure and ongoing hemodialysis. J Clin Microbiol 2005; 43: 3560-3563.
12. Hamaki T, Kami M, Kanda Y, Miyakoshi S, Ueyama J, Morinaga S, Mutuo Y. False-positive results of Aspergillus enzyme-linked immunosorbent assay in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 633-634.
13. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, Villard O, Liu KL, Natarajan-Ame S, Lutz R Dufour R Bergerat JP, Candolfi E. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002; 20: 1898-1906.
14. Klont RR, Meis JF, Verweij PE. Critical assessment of issues in the diagnosis of invasive aspergillosis. Clin Microbiol Infect 2001; 7(Suppl 2): 32-37.
15. Kozinn PJ, Taschdjian CL, Golberg PK, Protzmann WR Mackenzie DWR, Remington JS, Anderson S, Seeling MS. Efficiency of serologic tests in the diagnosis of systemic candidiasis. Am J Clin Pathol 1978; 70: 893-898.
16. th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington). Washington DC: American Society for Microbiology 2005: 459.
17. Maertens J, Theunissen K, Verbeken E, Lagrou K, Verhaegen J, Boogaerts M, van Eldere J. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant patients. Br J Haematol 2004; 126: 852-860.
18. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, van Eldere J. Galactomannan and computed tomographybased preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-1250.
19. Maertens J, Theunissen K, Verhoef G, van Eldere J. False-positive Aspergillus galactomannan antigen test results. Clin Infect Dis 2004; 39: 289-290.
20. Maertens J, van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogenic stem cell transplant recipients. J Infect Dis 2002; 186: 1297-1306.
21. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641-649.
22. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762-1769.
23. Mattei D, Rapezzi D, Mordini N, Cuda F, Lo Nigra C, Musso M, Arnelli A, Cagnassi S, Gallamini A. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol 2004; 42: 5362-5363.
24. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-357.
25. Mennink-Kersten MA, Klont RR, Warris A, Op den Camp HJM, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet 2004; 363: 325-327.
26. Metan G, Durusu M, Uzun O. False positivity for Aspergillus antigenemia with amoxicillin-clavulanic acid. J Clin Microbiol 2005; 43: 2548-2549.
27. Moreno JM, Alhambra A, Cuétara MS, Ortiz MC, Pontón J, del Palacio Perez Medel A, del Palacio A. Incidence of invasive fungal infection in adult haematological malignancy: a prospective validation of a risk stratification scheme. Br J Haematol 2006; 134: 343-345.
28. Del Palacio A, Cuétara MS, Pontón J. El diagnóstico de laboratorio de la aspergilosis invasora. Rev Iberoam Micol 2003; 20: 90-98.
29. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005; 366: 1013-1025.
30. De Pauw B. Between over- and under treatment of invasive fungal disease. Clin Infect Dis 2005; 41: 1251-1253.
31. Pazos C, Del Palacio A. Diagnóstico precoz de la aspergilosis invasora en enfermos neutropénicos mediante la detección bisemanal de galactomanano en suero con Platelia® Aspergillus. Rev Iberoam Micol 2003; 20: 99-102
32. Pazos C, Pontón J, del Palacio A. Contribution of 1-3-β-D glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299-305.
33. Penack O, Schwartz S, Thiel E, Blau IW. Lack of evidence that false-positive Aspergillus galactomannan antigen test results are due to treatment with pieracillin-tazobactam. Clin infect Dis 2004; 39: 1401-1402.
34. Pfeiffer CH, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1428-1430.
35. Pinel C, Fricker-Hidalgo H, Lebeau B, Garban F, Hamidfar R, Ambroise-Thomas P, Grillot R. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J Clin Microbiol 2003; 41: 2184-2186.
36. Pizzo PA, Robichaud KJ, Gill FA, Witebsky G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-111.
37. Pontón J, del Palacio A. Influence of Candida colonization on the (1 → 3) β-D-glucan assay. Clin Infect Dis 2006; 43: 263-264.
38. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000; 110: 273-284.
39. Rex JH. Galactomannan and the diagnosis of invasive aspergillosis. Clin Infect Dis 2006; 42: 1428-1430.
40. Severens JL, Donnelly JP, Meis JFGM, de Vries Robbe PF, de Pauw BE, Verweij PE. Two strategies for managing invasive aspergillosis: a decision analysis. Clin Infect Dis 1997; 25: 1148-1154.
41. Singh N, Obman A, Husain S, Aspinall S, Mietzner S, Stout JE. Reactivity of Platelia Aspergillus galactomannan antigen with piperacillin- tazobactam: clinical implications based on achievable concentrations in serum. Antimicrob Agents Chemother 2004; 48: 1989-1992.
42. Stynen DA, Goris J, Sarfati J, Latgé JP. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995; 33: 497-500.
43. Sulahian AF, Boutboul F, Ribaud R Leblanc T, Lacroix C, Derovin F. Value of antigenic detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric haematology units during a 4 year prospective study. Cancer 2001; 91: 311-318.
44. Swanink CM, Meis JF, Rijs AI, Donnelly JP, Verweij PE. Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan. J Clin Microbiol 1997; 35: 257-260.
45. US Food and Drug Administration FDA. Clears rapid test for Aspergillus infection. US Food and Drug Administration. 2003.
46. Viscoli C, Machetti M, Cappellano P, Bucci B, Bruzzi P, van Lint MT, Bacigalupo A. False-positive galactomannan Platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-916.
47. Walsh TJ, Shoham S, Petraitiene R, Sein T, Schaufele R, Kekaher A, Murray H, Mya-San C, Bacher J, Petraitis V. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004; 42: 4744-4748.
48. Wu DH. Platelia Aspergillus assay and potential cross-reaction. Clin Infect Dis 2004; 39: 1402.